Follica
Follica is a Boston-based regenerative medicine platform company developing proprietary skin-disruption-based hair growth therapies for individuals with hair loss, differentiating itself from pharmaceutical approaches such as JAK inhibitors through a non-drug mechanism of action and dual at-home and integrated delivery formats.
- Company typePrivate
- Founded2005
- HeadquartersMendham, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Follica does
Follica, Inc. is a Boston-based, privately held regenerative medicine platform company developing proprietary hair growth therapies for individuals suffering from hair loss and alopecia. The company's core technology is a "Skin Disruption" approach, a novel method architecture designed to stimulate regenerative hair follicle responses, positioning it as a non-pharmaceutical alternative to drug-based interventions such as JAK inhibitors (e.g., Pfizer's LITFULO). The platform is structured to support both at-home self-administered use and an integrated clinician-delivered format, suggesting a dual commercial pathway once regulatory clearance is achieved.
Founded in 2005 and operating with a small team of 1-10 employees, Follica has raised approximately $24.1M across four disclosed funding rounds between 2008 and 2010, with Polaris Partners, PureTech Health, and InterWest Partners as the principal backers. The company's scientific founders include George Cotsarelis (a leading hair follicle stem cell researcher) and Rox Anderson (a Harvard/MGH dermatologist known for laser dermatology), with executive leadership drawn from the dermatology venture ecosystem, including Executive Chairman Neal Walker. The company is currently pre-commercial, with no disclosed revenue, no public pricing, and no announced regulatory filings; commercial inquiries are routed through a generic contact email rather than a transactional channel.
The go-to-market posture described in available materials is direct-to-consumer within a North American footprint, targeting a horizontal segment of individuals seeking regenerative hair growth treatments rather than enterprise or institutional buyers. There are no named customers, partnerships, distribution agreements, or product launches disclosed in the source data, and no capital has been publicly documented since late 2010, leaving the company's recent operating tempo, clinical progress, and capital structure ambiguous and dependent on direct management diligence.
Follica firmographics
Firmographics- Name
- Follica
- Legal name
- Follica, Inc.
- Website
- http://www.follicabio.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Follica is a Boston-based regenerative medicine platform company developing proprietary skin-disruption-based hair growth therapies for individuals with hair loss, differentiating itself from pharmaceutical approaches such as JAK inhibitors through a non-drug mechanism of action and dual at-home and integrated delivery formats.
- Ownership category
- akta.pro rank
Follica industry classification
Industry- Product category
- Regenerative Hair Loss Treatment
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth) (CRABABAE)
Keywords
Where Follica is headquartered
LocationHeadquarters
- HQ city
- Mendham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Follica business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Distribution channels1 record
Marketing channels1 record
Follica product offering
Product offeringCore offering
Follica develops a regenerative platform technology for hair growth based on a proprietary skin disruption methodology designed to stimulate regenerative hair follicle responses. The company is building both at-home and integrated treatment approaches intended for individuals experiencing hair loss, alopecia, and related conditions, positioning its offering as a non-pharmaceutical alternative to drug-based hair loss therapies.
Product overview
Follica is a regenerative platform company focused on hair growth treatments. The company operates from Boston, MA and is developing treatments centered on skin disruption technology for hair regeneration. The platform appears to offer both at-home and integrated approaches to treatment delivery.
Differentiator
Problem solved
Functional benefit
Products and services
- Regenerative Hair Growth Platform A regenerative platform treatment for hair growth based on proprietary skin disruption methodology, designed to stimulate regenerative hair follicle responses in individuals with hair loss, alopecia, and related conditions.
- At-Home Integrated Hair Growth Solution An at-home treatment offering designed to deliver Follica's regenerative hair growth therapy directly to consumers in a home-use setting.
Companies that use Follica
Customer profileSegments1 record
Ideal customer profiles1 record
Follica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Follica partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Follica competitors and assessment
Company assessmentDirect peers
- Histogen: Clinical-stage regenerative medicine company developing novel hair growth treatments. Directly comparable to Follica as a biotech using a non-pharmaceutical, regenerative mechanism to treat hair loss.
- Keeps: Direct-to-consumer hair loss treatment brand offering finasteride and minoxidil. Comparable to Follica's at-home distribution model targeting the same consumer hair-loss segment.
- dNovo: Early-stage biotech engineering hair follicle growth via regenerative biology. Directly comparable to Follica's skin-disruption and regenerative approach to hair loss.
- Aclaris Therapeutics: Clinical-stage dermatology company developing treatments for alopecia and other hair loss conditions. Comparable target indication and stage, with overlapping scientific focus on hair follicle biology.
- Stemson Therapeutics: Preclinical/early-clinical company developing iPSC-derived hair follicle regeneration. Closely comparable to Follica in pursuing a regenerative cell- and follicle-based approach to hair loss.
Broad incumbents
- Pfizer: Large pharmaceutical company with LITFOLO (JAK inhibitor), an approved alopecia areata therapy. Comparable as the dominant pharmaceutical incumbent competing in Follica's target indication.
- Johnson & Johnson: Consumer health incumbent through Rogaine (minoxidil) and other personal care brands. Comparable as the established consumer hair-growth incumbent Follica would compete against.
- Eli Lilly: Major pharma whose Olumiant (baricitinib) is approved for severe alopecia areata. Relevant incumbent competitor in the systemic-treatment segment of Follica's market.
Emerging players
- Cassiopea: Dermatology-focused company that has developed clascoterone (Winlevi) and explored androgenetic alopecia indications. Comparable as a specialty dermatology player with hair-loss relevance.
- Hims & Hers Health: Digital health company offering hair loss treatments (including finasteride) directly to consumers. Comparable as a direct-to-consumer hair-loss brand, though broader in scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
Follica social profiles
Digital presenceFollica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Follica leadership team
Management profileNumber of profiles
Profiles7 records
Follica funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Follica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Follica
What does Follica do?
Follica develops a regenerative platform technology for hair growth based on a proprietary skin disruption methodology designed to stimulate regenerative hair follicle responses. The company is building both at-home and integrated treatment approaches intended for individuals experiencing hair loss, alopecia, and related conditions, positioning its offering as a non-pharmaceutical alternative to drug-based hair loss therapies.
Is Follica a public or private company?
Follica is a private company. It is classified as venture growth investor backed and is currently operating.
When was Follica founded?
Follica was founded in 2005. It employs 1 to 10 people.
Where is Follica based?
Follica is headquartered in Mendham, United States, in the North America region.
Who are Follica's main competitors?
Direct peers on record are Histogen, Keeps, dNovo, Aclaris Therapeutics and Stemson Therapeutics. Broad incumbents are Pfizer, Johnson & Johnson and Eli Lilly. Emerging players are Cassiopea and Hims & Hers Health.
Does Follica have an API?
No public API is recorded for Follica.
What industry is Follica in?
Follica's product category is Regenerative Hair Loss Treatment. Its primary akta.pro industry code is CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 325411 and its SIC code is 2844.